Morgan Stanley and Manufacturers Life Insurance Company purchased a new position and reiterated an overweight rating for Monopar Therapeutics.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley and Manufacturers Life Insurance Company purchased a new position and reiterated an overweight rating for Monopar Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
-
Manufacturers Life Insurance Company
business
Related events
- Morgan Stanley, Jefferies Financial Group, and Manufacturers Life Insurance Company published reports and rating updates on a company, including an underweight rating and new stake purchases.
- Morgan Stanley restated its 'overweight' rating and price objective for RTX stock, concurrently reducing its holdings by 3.4%.
- Morgan Stanley raised its price target and maintained an overweight rating for Wingstop.
- Morgan Stanley lowered its rating for CAE Inc from equal weight to underweight on August 27, 2026.
- Morgan Stanley analyst provides Overweight rating for SpaceX.